CClinicalTrials.gg
CompletedNCT03458507InterfaceNMDUpdated Oct 8, 2019

Impact of the Type of Interface in Neuromuscular Patients Treated With Nocturnal Noninvasive Ventilation

An interventional study of Switch of nocturnal NIV interface in Neuromuscular Diseases and Alveolar Hypoventilation, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-10-08.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Nocturnal Non Invasive Ventilation (NIV) is the reference treatment for chronic alveolar hypoventilation in patients with neuro-muscular diseases. NIV can be provided by using different types of interfaces: Nasal masks are the most frequent type of interface used at home but oronasal masks are used by at least 25% of neuro-muscular patients mainly because of persistent unintentional mouth leaks. However, oronasal mask may cause persistent upper airway obstructive respiratory events because of the mechanical constraint on the chin induced by the traction of the straps that may push the mandible posteriorly during sleep.

No randomized study has specifically addressed the question of the impact of type of interface in patients with neuromuscular diseases treated by nocturnal NIV.

The investigators hypothesize that:

  1. the application of oronasal mask may jeopardize the pharyngeal patency in patients already proned to upper airway obstruction;
  2. the use of a nasal mask may improve upper airway stability and NIV efficacy while reducing side effects.

Authors objective will be to compare the impact of nasal mask versus oronasal mask on NIV efficacy and side-effects. Eligible patients are those with nocturnal NIV and neuromuscular disease.

After a scheduled hospital visit, patients willing to participate will undergo in random order 2 unattended nocturnal polygraphies under NIV at home: one polygraphy with nasal mask; one with an oronasal mask. Each polygraphy ans side effects assessment will be performed after one week of familiarization with each mask.

02

Conditions studied

  • Neuromuscular Diseases
  • Alveolar Hypoventilation

Keywords

  • Neuromuscular diseases
  • Non-invasive ventilation
  • Nasal mask
  • Oronasal mask
  • Alveolar hypoventilation
  • leaks
  • Sleep disorder breathing
  • Side effects
03

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adult patients (>18 years old)
  • Affected by slowly progressive neuro-muscular diseases (Becker muscular dystrophy, facio-scapulo-humeral dystrophy, limb-girdle dystrophy, myotonic dystrophy...) or relatively rapid progression (Duchenne muscular dystrophy).
  • Treated with nocturnal non-invasive ventilation (\<15 hours/day)
  • In stable state (no cardiorespiratory or ear-nose-throat event for at least 1 month before inclusion)

Exclusion criteria

Exclusion Criteria:

  • Rapidly progressive neuro-muscular diseases (such as ALS)
  • Severe nasal obstruction, maxillofacial deformities or previous upper airway surgery preventing the usage of one type of mask (nasal or oronasal), or, at the discretion of investigator, any other contraindication for using the other type of mask
  • NIV Daily use >15h/day
  • Unwillingness or inability to provide consent to participation
  • Curatorship
  • Subject in exclusion period of another study
  • Vulnerable person or legally protected adult.
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Usual interface

    Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week. Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week.

    Device: Switch of nocturnal NIV interface

  • Active comparator
    Alternative interface

    Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week. Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week.

    Device: Switch of nocturnal NIV interface

Interventions

  • DeviceSwitch of nocturnal NIV interface

    1. test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed. 2. Interface switch 3. unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System. The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction.

05

What researchers measure

Primary outcomes

  1. Mean nocturnal oxygen saturation (SpO2)

    Mean nocturnal SpO2, measured by oximetry.

    Time frame: After one week with each type of mask

Secondary outcomes

  1. % sleep recording with SpO2<90%

    Percentage of sleep recording spent with SpO2\<90% between oronasal mask versus nasal mask

    Time frame: After one week with each type of mask

  2. Oxygen Desaturation Index

    Oxygen desaturation index between oronasal mask versus nasal mask

    Time frame: After one week with each type of mask

  3. Mean nocturnal PtcCO2

    Mean nocturnal transcutaneous partial pressure in CO2 (PtcCO2) evaluated by capnography between oronasal mask versus nasal mask

    Time frame: After one week with each type of mask

  4. Mean mouth opening during sleep

    Mean mouth opening during sleep between oronasal mask versus nasal mask

    Time frame: After one week with each type of mask

  5. Non-intentional leaks

    Non-intentional leaks recorded by the NIV-device

    Time frame: After one week with each type of mask

  6. Side-effects of Continuous Positive Airway Pressure (CPAP)

    Side-effects reported by patients using a modified version of "Side Effect of CPAP inventory" (SECI) questionnaire. A French translation will be done by two bilingual investigators (one medical doctor, one linguist). This questionnaire consists of a list of 15 commonly reported side effects under CPAP. For each side effect, the patient is asked to rate the frequency (0-5), magnitude (0-5) and perceived impact on adherence (0-5) on a five-point Likert-type scale. Total score range : 0 to 225, with the higher score associated with the worst tolerance. Range for each of the fifteen side effects: 0 to 15, higher values always represent a worse outcome (all subscales results are summed to compute the total score)

    Time frame: After one week with each type of mask

06

Study locations

1 site
  • Grenoble-Alpes University hospital
    Grenoble, 38000, France
07

References and documents

Publications

  • Borel JC, Tamisier R, Dias-Domingos S, Sapene M, Martin F, Stach B, Grillet Y, Muir JF, Levy P, Series F, Pepin JL; Scientific Council of The Sleep Registry of the French Federation of Pneumology (OSFP). Type of mask may impact on continuous positive airway pressure adherence in apneic patients. PLoS One. 2013 May 15;8(5):e64382. doi: 10.1371/journal.pone.0064382. Print 2013. PubMed 23691209 ↗
  • Bakker JP, Neill AM, Campbell AJ. Nasal versus oronasal continuous positive airway pressure masks for obstructive sleep apnea: a pilot investigation of pressure requirement, residual disease, and leak. Sleep Breath. 2012 Sep;16(3):709-16. doi: 10.1007/s11325-011-0564-3. Epub 2011 Jul 29. PubMed 21800222 ↗
  • Borel JC, Gakwaya S, Masse JF, Melo-Silva CA, Series F. Impact of CPAP interface and mandibular advancement device on upper airway mechanical properties assessed with phrenic nerve stimulation in sleep apnea patients. Respir Physiol Neurobiol. 2012 Aug 15;183(2):170-6. doi: 10.1016/j.resp.2012.06.018. Epub 2012 Jul 3. PubMed 22772315 ↗
  • Willson GN, Piper AJ, Norman M, Chaseling WG, Milross MA, Collins ER, Grunstein RR. Nasal versus full face mask for noninvasive ventilation in chronic respiratory failure. Eur Respir J. 2004 Apr;23(4):605-9. doi: 10.1183/09031936.04.00051604. PubMed 15083762 ↗
  • Fleck RJ Jr, Mahmoud M, McConnell K, Shott SR, Gutmark E, Amin RS. An adverse effect of positive airway pressure on the upper airway documented with magnetic resonance imaging. JAMA Otolaryngol Head Neck Surg. 2013 Jun;139(6):636-8. doi: 10.1001/jamaoto.2013.3279. PubMed 23787424 ↗
  • Vrijsen B, Buyse B, Belge C, Testelmans D. Upper airway obstruction during noninvasive ventilation induced by the use of an oronasal mask. J Clin Sleep Med. 2014 Sep 15;10(9):1033-5. doi: 10.5664/jcsm.4046. PubMed 25142771 ↗
  • Leotard A, Lebret M, Daabek N, Prigent H, Destors M, Saint-Raymond C, Sagniez A, Leroux K, Tamisier R, Lofaso F, Pepin JL, Borel JC. Impact of Interface Type on Noninvasive Ventilation Efficacy in Patients With Neuromuscular Disease: A Randomized Cross-Over Trial. Arch Bronconeumol (Engl Ed). 2021 Apr;57(4):273-280. doi: 10.1016/j.arbres.2020.05.024. Epub 2020 Jun 23. English, Spanish. PubMed 32586702 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03458507
Lead sponsor
University Hospital, Grenoble
Collaborators
Association Française contre les Myopathies (AFM), Paris, Hôpital Raymond Poincaré
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
May 28, 2018
Primary completion
Jun 28, 2018
Completion
Jun 26, 2019
Last update
Oct 8, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion